// App-Quantinova.ai

2439 : The BCR-ABL Fusion Protein Sensitizes Acute Lymphoblastic Leukemia to Apoptotic Death Induced by the Dual Glycolytic and Glycosylation Inhibitor 2-Deoxy-D-Glucose.

Researchers

Presenter

  • Jianfeng Du

Principal Investigators

  • Joanna DeSalvo

  • Gilles M. Leclerc

  • Julio C. Barredo

Medical Centers

  • Microbiology and Immunology, University of Miami Miller School of Medicine, Miami, FL

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • Solid malignancies

Biomarkers

  • Myeloid Cell Leukemia 1

  • Breakpoint Cluster Region

  • Nucleoside diphosphate kinase A

  • Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform

  • Phosphorylated signal transducer and activator of transcription 3

  • Phosphorylated-mechanistic target of rapamycin

  • DNA Damage Inducible Transcript 3

Drug/Treatment

  • 2-Deoxy-D-Glucose

  • Imatinib

  • IkT001

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved